Aino Health Valuation

Is AINO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AINO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AINO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AINO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AINO?

Key metric: As AINO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AINO. This is calculated by dividing AINO's market cap by their current revenue.
What is AINO's PS Ratio?
PS Ratio	1.1x
Sales	SEK 24.26m
Market Cap	SEK 27.72m

AINO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	-3.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AINO's PS Ratio compare to its peers?

The above table shows the PS ratio for AINO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.7x
RIGHTB RightBridge Ventures Group	3.8x	n/a	SEK 12.0m
QCORE Qlucore	0.7x	n/a	SEK 23.0m
ORTI B Ortivus	1x	n/a	SEK 81.5m
MEDHLP Medhelp Care Aktiebolag	1.1x	6.8%	SEK 99.8m
AINO Aino Health	1.1x	n/a	SEK 27.7m

Price-To-Sales vs Peers: AINO is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does AINO's PS Ratio compare vs other companies in the European Healthcare Services Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: AINO is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is AINO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AINO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AINO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Arcoma

SEK 146.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 11.10

5.7%

53.1%

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.19

8.2%

-44.7%

Iconovo

SEK 80.5m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.06

-0.8%

-45.4%